Biotechnology Patent Group Chair, Shareholder
Denver Colorado UNITED STATES
Dr. Timothy Worrall is a U.S. and international patent strategist, and chairs the Polsinelli Biotechnology group. His professional summary includes, Intellectual property patent portfolio development, strategy, and prosecution with a focus on biotechnology, chemistry, material science, and analytical instrumentation; focus on developing patent portfolios that can be leveraged defensively to protect a client’s existing innovation, and offensively to protect intellectual property in a broader commercial space; life cycle management of products, assays, and devices in domestic and international contexts; In the pharmaceutical and biotechnology sectors, Dr. Worrall helps innovators protect and maximize the life cycle of pharmaceuticals and biotechnology products, assays, and devices. His practice centres around developing and procuring national and worldwide patent portfolios that extend the value of developing technology. He works closely with attorneys in the patent litigation practice to develop portfolios capable of withstanding litigation, and with the firm's FDA practice to develop non-patent exclusivity. Dr. Worrall holds a Ph.D. in Biophysics and Biophysical Chemistry from the Johns Hopkins University School of Medicine, and a J.D. and Certificate in Intellectual Property from the University of California-Berkeley (Boalt Hall). Prior to attending law school, he was a patent examiner at the United States Patent and Trademark Office. Dr Worrall 's recent publications include: 2018 Association of University Technology Managers, Eastern Region Meeting: Panel Moderator and Presenter, Pathways to Success for the University in Therapeutics and Diagnostics; 2018 Presenter, 9th Annual ACI Biosimilars Conference Creating and Destroying the Patent Thicket: International Patent Strategies for Biosimilars; 2018 BIO International Conference: Current International Aspects of Legal Practice in Europe, Korea, and the U.S.; Moderator and Presenter.
None yet.